Nairametrics
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
  • Home
  • Exclusives
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
  • Markets
    • Cryptos
    • Commodities
    • Equities
      • Dividends
      • Stock Market
    • Fixed Income
    • Market Views
    • Securities
  • Industries
    • Company News
    • Consumer Goods
    • Content Partners
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Tech News
  • Economy
    • Get Data
    • Macro-Economic News
    • Research Analysis
  • Business News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Op-Eds
No Result
View All Result
Nairametrics
No Result
View All Result
Home Business News Coronavirus

Pfizer, BioNTech say their Covid-19 vaccine is over 90% effective in phase 3 trial

Chike Olisah by Chike Olisah
November 9, 2020
in Coronavirus, Spotlight
Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly, Vaccine, COVID-19: Russia to roll out vaccine in September ahead of the West 

Covid-19: AstraZeneca vaccine gets huge boost, produces immune response in elderly

Share on FacebookShare on TwitterShare on Linkedin

Pfizer Inc had on Monday disclosed that its experimental vaccine which it is jointly developing with BioNTech was more than 90% effective in preventing COVID-19 based on initial data from a large study, in the ongoing phase 3 trials.

This is a major victory in the fight against a pandemic that has killed over 1 million people, negatively impacted on the world’s economy and upended daily life.

READ: Covid-19: AstraZenca drugs aims to be ready for large-scale vaccination this year

RelatedPosts

Canada donates 2.6 million doses of COVID-19 vaccines to Nigeria

World Bank says COVID-19 sparked surge in financial inclusion globally

This disclosure was made in a statement by the Chairman and Chief Executive Officer of Pfizer, Albert Bourla, on Monday, November 9, 2020.

Pfizer and German partner BioNTech SE are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine. The companies said they have so far found no serious safety concerns and expect to seek U.S. emergency use authorization later this month.

News continues after this ad


If authorized, the number of vaccine doses will initially be limited. Many questions also remain including how long the vaccine will provide protection. However, the news provides hope that other vaccines in development against the novel coronavirus may also prove effective.

READ: COVID-19: US to have enough vaccines for vulnerable Americans by end of 2020

News continues after this ad


Albert Bourla, in his statement, said, “Today is a great day for science and humanity. We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen.”

He said that the first set of results from the Phase 3 Covid-19 vaccine trial provides the initial evidence of their vaccine’s ability to prevent Covid-19

READ: Airsmat berths artificial intelligence platform to improve farm output

Pfizer expects to seek broad U.S. emergency use authorization of the vaccine for people aged 16 to 85. To do so, it will need to have collected two months of safety data on around half of the study’s roughly 44,000 participants, expected in late November.

Bill Gruber, one of Pfizer’s top vaccine scientists, said in an interview, ‘’I’m near ecstatic. This is a great day for public health and for the potential to get us all out of the circumstances we’re now in.”

READ: NCC grants national roaming services approval to MTN, 9mobile

Pfizer said the interim analysis was conducted after 94 participants in the trial developed COVID-19, examining how many of them received the vaccine versus placebo.

Details later…

Related

Tags: Business NewsCovid-19Pfizer Inc.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

inq
avatrade
Stanbic bank
Mega Millions
UBN
Hot forex
Access Bank
Bankers Committee
First bank






    Business News | Stock Market | Money Market | Cryptos | Financial Literacy | SME |

    Recent News

    • Gains from MTN not enough to stop Nigeria’s stock market from shedding N95 billion
    • ChamsSwitch gets Visa recognition, enlisted on Visa Global Registry
    • 3 ways to solve electricity crisis in Nigeria – Atiku Abubakar

    Follow us on social media:

    Recent News

    Stock News

    Gains from MTN not enough to stop Nigeria’s stock market from shedding N95 billion

    August 19, 2022
    ChamsSwitch gets Visa recognition, enlisted on Visa Global Registry

    ChamsSwitch gets Visa recognition, enlisted on Visa Global Registry

    August 19, 2022
    • ABOUT US
    • CONTACT US
    • PRODUCTS
    • ANDROID APP
    • iOS APP
    • DISCLAIMER
    • CAREERS
    • PRIVACY POLICY

    © 2022 Nairametrics

    No Result
    View All Result
    • Home
    • Exclusives
      • Financial Analysis
      • Corporate Stories
      • Interviews
      • Investigations
      • Metrics
    • Markets
      • Cryptos
      • Commodities
      • Equities
        • Dividends
        • Stock Market
      • Fixed Income
      • Market Views
      • Securities
    • Industries
      • Company News
      • Consumer Goods
      • Content Partners
      • Corporate deals
      • Corporate Press Releases
      • Energy
      • Entertainment
      • Financial Services
      • Hospitality & Travel
      • Manufacturing
      • Real Estate and Construction
      • Tech News
    • Economy
      • Get Data
      • Macro-Economic News
      • Research Analysis
    • Business News
    • Financial Literacy
      • Career tips
      • Personal Finance
    • Lifestyle
      • Billionaire Watch
      • Profiles
    • Opinions
      • Blurb
      • Op-Eds

    © 2022 Nairametrics

    Social Media Auto Publish Powered By : XYZScripts.com